Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Distinct Roles for Peyer's Patch B Cells for Induction of Antigen-specific IgA Antibody Responses in Mice Administered Oral Recombinant Salmonella.

Hashizume-Takizawa T, Shibata N, Kurashima Y, Kiyono H, Kurita-Ochiai T, Fujihashi K.

Int Immunol. 2019 Mar 14. pii: dxz029. doi: 10.1093/intimm/dxz029. [Epub ahead of print]

PMID:
30868152
2.

Transcutaneous immunization with pneumococcal surface protein A in mice.

Nagano H, Kawabata M, Sugita G, Tsuruhara A, Ohori J, Jimura T, Miyashita K, Kurono Y, Tomonaga K, Briles DE, Fujihashi K.

Laryngoscope. 2018 Mar;128(3):E91-E96. doi: 10.1002/lary.26971. Epub 2017 Dec 11.

PMID:
29226330
3.

Rectal administration of a chlamydial subunit vaccine protects against genital infection and upper reproductive tract pathology in mice.

Pais R, Omosun Y, He Q, Blas-Machado U, Black C, Igietseme JU, Fujihashi K, Eko FO.

PLoS One. 2017 Jun 1;12(6):e0178537. doi: 10.1371/journal.pone.0178537. eCollection 2017.

4.

Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.

Kataoka K, Fukuyama Y, Briles DE, Miyake T, Fujihashi K.

Microbiol Immunol. 2017 Jun;61(6):195-205. doi: 10.1111/1348-0421.12487. Review.

5.

Rejuvenation of mucosal immunosenescence by adipose tissue-derived mesenchymal stem cells.

Tsuruhara A, Aso K, Tokuhara D, Ohori J, Kawabata M, Kurono Y, McGhee JR, Fujihashi K.

Int Immunol. 2017 Jan 1;29(1):5-10. doi: 10.1093/intimm/dxx001. Review.

6.

The effects of differences in pspA alleles and capsular types on the resistance of Streptococcus pneumoniae to killing by apolactoferrin.

Mirza S, Benjamin WH Jr, Coan PA, Hwang SA, Winslett AK, Yother J, Hollingshead SK, Fujihashi K, Briles DE.

Microb Pathog. 2016 Oct;99:209-219. doi: 10.1016/j.micpath.2016.08.029. Epub 2016 Aug 26.

PMID:
27569531
7.

Adipose-Derived Mesenchymal Stem Cells Restore Impaired Mucosal Immune Responses in Aged Mice.

Aso K, Tsuruhara A, Takagaki K, Oki K, Ota M, Nose Y, Tanemura H, Urushihata N, Sasanuma J, Sano M, Hirano A, Aso R, McGhee JR, Fujihashi K.

PLoS One. 2016 Feb 3;11(2):e0148185. doi: 10.1371/journal.pone.0148185. eCollection 2016.

8.

A molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderly.

Fukuyama Y, Ikeda Y, Ohori J, Sugita G, Aso K, Fujihashi K, Briles DE, McGhee JR, Fujihashi K.

Immune Netw. 2015 Feb;15(1):9-15. doi: 10.4110/in.2015.15.1.9. Epub 2015 Feb 17. Review.

9.

Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques.

Fukuyama Y, Yuki Y, Katakai Y, Harada N, Takahashi H, Takeda S, Mejima M, Joo S, Kurokawa S, Sawada S, Shibata H, Park EJ, Fujihashi K, Briles DE, Yasutomi Y, Tsukada H, Akiyoshi K, Kiyono H.

Mucosal Immunol. 2015 Sep;8(5):1144-53. doi: 10.1038/mi.2015.5. Epub 2015 Feb 11.

10.

Mucosal Immunosenescence in the Gastrointestinal Tract: A Mini-Review.

Sato S, Kiyono H, Fujihashi K.

Gerontology. 2015;61(4):336-42. doi: 10.1159/000368897. Epub 2014 Dec 20. Review.

11.

A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.

Gu L, Krendelchtchikova V, Krendelchtchikov A, Oster RA, Fujihashi K, Matthews QL.

Virol J. 2014 Jun 16;11:112. doi: 10.1186/1743-422X-11-112.

12.

Mucosal adjuvants for vaccines to control upper respiratory infections in the elderly.

Fujihashi K, Sato S, Kiyono H.

Exp Gerontol. 2014 Jun;54:21-6. doi: 10.1016/j.exger.2014.01.006. Epub 2014 Jan 16. Review.

13.

Antibodies mediate formation of neutrophil extracellular traps in the middle ear and facilitate secondary pneumococcal otitis media.

Short KR, von Köckritz-Blickwede M, Langereis JD, Chew KY, Job ER, Armitage CW, Hatcher B, Fujihashi K, Reading PC, Hermans PW, Wijburg OL, Diavatopoulos DA.

Infect Immun. 2014 Jan;82(1):364-70. doi: 10.1128/IAI.01104-13. Epub 2013 Nov 4.

14.

Potential roles of CCR5(+) CCR6(+) dendritic cells induced by nasal ovalbumin plus Flt3 ligand expressing adenovirus for mucosal IgA responses.

Fukuyama Y, Tokuhara D, Sekine S, Aso K, Kataoka K, Davydova J, Yamamoto M, Gilbert RS, Tokuhara Y, Fujihashi K, Kunisawa J, Yuki Y, Kiyono H, McGhee JR, Fujihashi K.

PLoS One. 2013;8(4):e60453. doi: 10.1371/journal.pone.0060453. Epub 2013 Apr 2.

15.

Inside the mucosal immune system.

McGhee JR, Fujihashi K.

PLoS Biol. 2012;10(9):e1001397. doi: 10.1371/journal.pbio.1001397. Epub 2012 Sep 25.

17.

Novel vaccine development strategies for inducing mucosal immunity.

Fujkuyama Y, Tokuhara D, Kataoka K, Gilbert RS, McGhee JR, Yuki Y, Kiyono H, Fujihashi K.

Expert Rev Vaccines. 2012 Mar;11(3):367-79. doi: 10.1586/erv.11.196. Review.

18.

Notch-ligand expression by NALT dendritic cells regulates mucosal Th1- and Th2-type responses.

Fukuyama Y, Tokuhara D, Sekine S, Kataoka K, Markham JD, Irwin AR, Moon GH, Tokuhara Y, Fujihashi K, Davydova J, Yamamoto M, Gilbert RS, Fujihashi K.

Biochem Biophys Res Commun. 2012 Feb 3;418(1):6-11. doi: 10.1016/j.bbrc.2011.12.046. Epub 2011 Dec 19.

19.

A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging.

Asanuma H, Zamri NB, Sekine S, Fukuyama Y, Tokuhara D, Gilbert RS, Fukuiwa T, Fujihashi K, Sata T, Tashiro M, Fujihashi K.

Vaccine. 2012 Jan 17;30(4):803-12. doi: 10.1016/j.vaccine.2011.10.093. Epub 2011 Nov 17.

20.

Functional transforming growth factor-β receptor type II expression by CD4+ T cells in Peyer's patches is essential for oral tolerance induction.

Gilbert RS, Kobayashi R, Sekine S, Fujihashi K.

PLoS One. 2011;6(11):e27501. doi: 10.1371/journal.pone.0027501. Epub 2011 Nov 7.

21.

Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.

Hong SH, Byun YH, Nguyen CT, Kim SY, Seong BL, Park S, Woo GJ, Yoon Y, Koh JT, Fujihashi K, Rhee JH, Lee SE.

Vaccine. 2012 Jan 5;30(2):466-74. doi: 10.1016/j.vaccine.2011.10.058. Epub 2011 Oct 31.

PMID:
22051136
22.

Oral-nasopharyngeal dendritic cells mediate T cell-independent IgA class switching on B-1 B cells.

Kataoka K, Fujihashi K, Terao Y, Gilbert RS, Sekine S, Kobayashi R, Fukuyama Y, Kawabata S, Fujihashi K.

PLoS One. 2011;6(9):e25396. doi: 10.1371/journal.pone.0025396. Epub 2011 Sep 29.

23.

Elicitation of mucosal immunity by proteins of Streptococcus pneumoniae.

Briles DE, Miyaji E, Fukuyama Y, Ferreira DM, Fujihashi K.

Adv Otorhinolaryngol. 2011;72:25-7. doi: 10.1159/000324589. Epub 2011 Aug 18.

PMID:
21865682
24.

Mucosal immune features to phosphorylcholine by nasal Flt3 ligand cDNA-based vaccination.

Baatarjav T, Kataoka K, Gilbert RS, Terao Y, Fukui M, Goto M, Kawabata S, Yamamoto M, Fujihashi K, Ito HO.

Vaccine. 2011 Aug 5;29(34):5747-57. doi: 10.1016/j.vaccine.2011.05.097. Epub 2011 Jun 15.

PMID:
21683111
25.

The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.

Kataoka K, Fujihashi K, Oma K, Fukuyama Y, Hollingshead SK, Sekine S, Kawabata S, Ito HO, Briles DE, Oishi K.

Infect Immun. 2011 Jul;79(7):2819-28. doi: 10.1128/IAI.01360-10. Epub 2011 May 2.

26.

Induction of IL-10-producing CD4+ T-cells in chronic periodontitis.

Kobayashi R, Kono T, Bolerjack BA, Fukuyama Y, Gilbert RS, Fujihashi K, Ruby J, Kataoka K, Wada M, Yamamoto M, Fujihashi K.

J Dent Res. 2011 May;90(5):653-8. doi: 10.1177/0022034510397838. Epub 2011 Feb 18.

27.

A combination of Flt3 ligand cDNA and CpG oligodeoxynucleotide as nasal adjuvant elicits protective secretory-IgA immunity to Streptococcus pneumoniae in aged mice.

Fukuyama Y, King JD, Kataoka K, Kobayashi R, Gilbert RS, Hollingshead SK, Briles DE, Fujihashi K.

J Immunol. 2011 Feb 15;186(4):2454-61. doi: 10.4049/jimmunol.1002837. Epub 2011 Jan 17.

28.

Mucosal regulatory cells in the gastrointestinal tract and periodontium.

Takahashi I, Fujihashi K, Kiyono H.

Periodontol 2000. 2010 Oct;54(1):247-56. doi: 10.1111/j.1600-0757.2009.00335.x. No abstract available.

PMID:
20712644
29.

Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae.

Fukuyama Y, King JD, Kataoka K, Kobayashi R, Gilbert RS, Oishi K, Hollingshead SK, Briles DE, Fujihashi K.

J Immunol. 2010 Aug 1;185(3):1755-62. doi: 10.4049/jimmunol.1000831. Epub 2010 Jun 28.

30.

Oral immunization with Porphyromonas gingivalis outer membrane protein and CpGoligodeoxynucleotides elicits T helper 1 and 2 cytokines for enhanced protective immunity.

Liu C, Hashizume T, Kurita-Ochiai T, Fujihashi K, Yamamoto M.

Mol Oral Microbiol. 2010 Jun;25(3):178-89. doi: 10.1111/j.2041-1014.2009.00560.x.

31.

Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus.

Takahashi E, Kataoka K, Fujii K, Chida J, Mizuno D, Fukui M, Hiro-O Ito, Fujihashi K, Kido H.

Microbes Infect. 2010 Sep;12(10):778-83. doi: 10.1016/j.micinf.2010.04.013. Epub 2010 May 7.

PMID:
20452454
32.

Indigenous opportunistic bacteria inhabit mammalian gut-associated lymphoid tissues and share a mucosal antibody-mediated symbiosis.

Obata T, Goto Y, Kunisawa J, Sato S, Sakamoto M, Setoyama H, Matsuki T, Nonaka K, Shibata N, Gohda M, Kagiyama Y, Nochi T, Yuki Y, Fukuyama Y, Mukai A, Shinzaki S, Fujihashi K, Sasakawa C, Iijima H, Goto M, Umesaki Y, Benno Y, Kiyono H.

Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7419-24. doi: 10.1073/pnas.1001061107. Epub 2010 Apr 1.

33.

Fusobacterium nucleatum envelope protein FomA is immunogenic and binds to the salivary statherin-derived peptide.

Nakagaki H, Sekine S, Terao Y, Toe M, Tanaka M, Ito HO, Kawabata S, Shizukuishi S, Fujihashi K, Kataoka K.

Infect Immun. 2010 Mar;78(3):1185-92. doi: 10.1128/IAI.01224-09. Epub 2009 Dec 14.

34.

A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota.

Cong Y, Feng T, Fujihashi K, Schoeb TR, Elson CO.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19256-61. doi: 10.1073/pnas.0812681106. Epub 2009 Nov 4.

35.

Id2-, RORgammat-, and LTbetaR-independent initiation of lymphoid organogenesis in ocular immunity.

Nagatake T, Fukuyama S, Kim DY, Goda K, Igarashi O, Sato S, Nochi T, Sagara H, Yokota Y, Jetten AM, Kaisho T, Akira S, Mimuro H, Sasakawa C, Fukui Y, Fujihashi K, Akiyama T, Inoue J, Penninger JM, Kunisawa J, Kiyono H.

J Exp Med. 2009 Oct 26;206(11):2351-64. doi: 10.1084/jem.20091436. Epub 2009 Oct 12.

36.

Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines.

Kataoka K, Fujihashi K.

Expert Rev Vaccines. 2009 Sep;8(9):1183-93. doi: 10.1586/erv.09.80. Review.

37.

Oral MucoRice expressing double-mutant cholera toxin A and B subunits induces toxin-specific neutralising immunity.

Yuki Y, Tokuhara D, Nochi T, Yasuda H, Mejima M, Kurokawa S, Takahashi Y, Kataoka N, Nakanishi U, Hagiwara Y, Fujihashi K, Takaiwa F, Kiyono H.

Vaccine. 2009 Oct 9;27(43):5982-8. doi: 10.1016/j.vaccine.2009.07.071. Epub 2009 Aug 7.

PMID:
19665603
38.

Mucosal immunosenescence: new developments and vaccines to control infectious diseases.

Fujihashi K, Kiyono H.

Trends Immunol. 2009 Jul;30(7):334-43. doi: 10.1016/j.it.2009.04.004. Epub 2009 Jun 18. Review.

PMID:
19540811
39.

Co-administration of cholera toxin and apple polyphenol extract as a novel and safe mucosal adjuvant strategy.

Yoshino N, Fujihashi K, Hagiwara Y, Kanno H, Takahashi K, Kobayashi R, Inaba N, Noda M, Sato S.

Vaccine. 2009 Jul 30;27(35):4808-17. doi: 10.1016/j.vaccine.2009.05.081. Epub 2009 Jun 17.

PMID:
19539583
40.

Preferential use of DH reading frame 2 alters B cell development and antigen-specific antibody production.

Schelonka RL, Zemlin M, Kobayashi R, Ippolito GC, Zhuang Y, Gartland GL, Szalai A, Fujihashi K, Rajewsky K, Schroeder HW Jr.

J Immunol. 2008 Dec 15;181(12):8409-15.

41.

A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity.

Fukuiwa T, Sekine S, Kobayashi R, Suzuki H, Kataoka K, Gilbert RS, Kurono Y, Boyaka PN, Krieg AM, McGhee JR, Fujihashi K.

Vaccine. 2008 Sep 2;26(37):4849-59. doi: 10.1016/j.vaccine.2008.06.091. Epub 2008 Jul 14.

42.

Ovalbumin-protein sigma 1 M-cell targeting facilitates oral tolerance with reduction of antigen-specific CD4+ T cells.

Suzuki H, Sekine S, Kataoka K, Pascual DW, Maddaloni M, Kobayashi R, Fujihashi K, Kozono H, McGhee JR, Fujihashi K.

Gastroenterology. 2008 Sep;135(3):917-25. doi: 10.1053/j.gastro.2008.05.037. Epub 2008 May 15.

43.

A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration.

Sekine S, Kataoka K, Fukuyama Y, Adachi Y, Davydova J, Yamamoto M, Kobayashi R, Fujihashi K, Suzuki H, Curiel DT, Shizukuishi S, McGhee JR, Fujihashi K.

J Immunol. 2008 Jun 15;180(12):8126-34.

44.

Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1.

Rynda A, Maddaloni M, Mierzejewska D, Ochoa-Repáraz J, Maslanka T, Crist K, Riccardi C, Barszczewska B, Fujihashi K, McGhee JR, Pascual DW.

J Immunol. 2008 Apr 15;180(8):5187-200.

45.

Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.

Asanuma H, Fujihashi K, Miyakoshi T, Yoshikawa T, Fujita-Yamaguchi Y, Kojima N, Nakata M, Suzuki Y, Tamura S, Kurata T, Sata T.

Vaccine. 2007 Sep 28;25(39-40):6975-80. Epub 2007 Jul 16.

PMID:
17716790
46.

A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.

Youn HJ, Ko SY, Lee KA, Ko HJ, Lee YS, Fujihashi K, Boyaka PN, Kim SH, Horimoto T, Kweon MN, Kang CY.

Vaccine. 2007 Jul 9;25(28):5189-98. Epub 2007 May 21.

PMID:
17548137
47.

Nasal cholera toxin elicits IL-5 and IL-5 receptor alpha-chain expressing B-1a B cells for innate mucosal IgA antibody responses.

Kataoka K, Fujihashi K, Sekine S, Fukuiwa T, Kobayashi R, Suzuki H, Nagata H, Takatsu K, Shizukuishi S, McGhee JR, Fujihashi K.

J Immunol. 2007 May 15;178(10):6058-65.

48.

Mucosal vaccine development for botulinum intoxication.

Fujihashi K, Staats HF, Kozaki S, Pascual DW.

Expert Rev Vaccines. 2007 Feb;6(1):35-45. Review.

PMID:
17280477
49.

Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease.

Kim HD, Tahara K, Maxwell JA, Lalonde R, Fukuiwa T, Fujihashi K, Van Kampen KR, Kong FK, Tang DC, Fukuchi K.

J Gene Med. 2007 Feb;9(2):88-98.

50.

Type 1 and 2 T helper cell-mediated colitis.

Dohi T, Fujihashi K.

Curr Opin Gastroenterol. 2006 Nov;22(6):651-7. Review.

PMID:
17053444

Supplemental Content

Loading ...
Support Center